Real world treatment patterns of first-line combination therapies among BRAF+ metastatic melanoma patients stratified by tumor burden.

Authors

null

Sameer Ghate

Novartis Pharmaceuticals Corporation, East Hanover, NJ

Sameer Ghate, Jackson Tang, Zhiyi Li, Antonio Reis Nakasato

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies

Sub Track

Immune Checkpoints and Stimulatory Receptors

Citation

J Clin Oncol 36, 2018 (suppl 5S; abstr 198)

DOI

10.1200/JCO.2018.36.5_suppl.198

Abstract #

198

Poster Bd #

K7

Abstract Disclosures

Similar Posters

Poster

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Real world treatment patterns of first-line combination therapies among BRAF+ metastatic melanoma patients.

Real world treatment patterns of first-line combination therapies among BRAF+ metastatic melanoma patients.

First Author: Sameer Ghate

First Author: Jason J. Luke